DFX Intelligence
Venture Capital Intelligence
Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.
Firms / Invivium Capital
Invivium Capital
We are healthcare investors with the belief that there is significant opportunity for groundbreaking innovation to bring meaningful and lasting change to our lives, to our health and to the care that we receive.
venture manager, reported GAV $26.5M across 1 vehicles
Importance
14
low
Active deployment
19
moderate
Emerging
63
high
Completeness
63
high
Freshness
100
high
Research priority
23
moderate
Identity and regulatory footprint
- Headquarters
- Chicago, ILadviserinfo.sec.gov
- Office address
- 400 N ABERDEEN ST, SUITE 900, Chicago, IL, 60642-6549adviserinfo.sec.gov
- Business phone
- 312-210-0022adviserinfo.sec.gov
- Website
- https://www.invivium.com/
- SEC adviser type
- exempt reporting adviseradviserinfo.sec.gov
- SEC exemption claimed
- venture capital fund adviseradviserinfo.sec.govItem 2.B(1): advises solely venture capital funds
- Latest Form ADV
- Mar 12, 2026
- Private funds reported
- 1 (1 venture capital funds)adviserinfo.sec.gov
- Private fund gross assets
- $34.1Madviserinfo.sec.govreported GAV of the funds, the adviser's own number; not fund size, not dry powder
- business email
- info@invivium.cominvivium.compublished by the subject
- business phone
- 312-210-0022adviserinfo.sec.govpublished by the subject
Stated thesis versus observed behaviour
5 observed deals
Stated (the firm’s website)
- Sectors
- healthcare, biotech
- Stages
- not stated or not yet read
- Geography
- chicago
- Check size
- not stated; DFX does not estimate checks from round sizes
- Self-described
- venture capital
Observed (from deals on record)
Stage at participation: no observed deals yet
Stage at first entry: no observed deals yet
Sectors
unknown 60%Biotechnology 20%Pharmaceuticals 20%
lead rate n/afollow-on rate n/anew logos, 12 months 5
Funds and vehicles
1 reported
| Vehicle | Type | Vintage | Lifecycle | Reported GAV | Owners | Form D sold | Latest Form D |
|---|---|---|---|---|---|---|---|
| Invivium Capital, LP | Fund | unknown | Unknown | $26.5M Mar 25, 2024 | 57 | $0 | Jul 25, 2023 |
GAV is the gross asset value the adviser reported on Form ADV for the vehicle, never the fund’s committed size and never dry powder. Form D sold is the amount sold as of the latest filing, never a final close.
Investment team
8 current, 1 departed
Christine Neipert
Board or advisoryJ.D., Ph.D., IP Advisor
Michael Liang
Managing partnerManaging Partner
Michael N Liang
Managing partnerManaging Member · since Jul 1, 2023
Shahryar Oveissi
Operating partnerOperating Partner
Amy Len Kobe
PartnerPartner
Christopher Cox
PartnerPartner
Nicole Frances Bramson
PartnerMember · since Jul 1, 2023
Alyse Passaglia
Platform and operationsVice President of HR & Operations
1 departed (kept with end dates)
- Michael Liang · Managing Partner · ? to Sep 16, 2026 Inference
Investments on record
5 edges, 5 companies, 0 partner-attributed
| Company | Round | Role | Partner | Round size | This investor | Date | Source |
|---|---|---|---|---|---|---|---|
| Alto Neuroscience, Inc. | portfolio listing | unknown | unknown | unknown | unknown | Sep 16, 2026 | Fact Venture organization websites (about, team, portfolio, thesis, news pages) |
| Avalyn Pharma | portfolio listing | unknown | unknown | unknown | unknown | Sep 16, 2026 | Fact Venture organization websites (about, team, portfolio, thesis, news pages) |
| Grove Biopharma | portfolio listing | unknown | unknown | unknown | unknown | Sep 16, 2026 | Fact Venture organization websites (about, team, portfolio, thesis, news pages) |
| Hinge Bio, Inc. | portfolio listing | unknown | unknown | unknown | unknown | Sep 16, 2026 | Fact Venture organization websites (about, team, portfolio, thesis, news pages) |
| Revelyx Bio | portfolio listing | unknown | unknown | unknown | unknown | Sep 16, 2026 | Fact Venture organization websites (about, team, portfolio, thesis, news pages) |
“This investor” is the amount disclosed for this investor alone; it is unknown unless a source said it. The round size is the whole round.
Co-investors
1 relationships from shared deals, counted for the whole firm
Limited partners
0 disclosed
No LP commitment on record. An LP edge needs a public disclosure with a quote: a pension report (see Limited partners for the plans read), a fund announcement naming the LP, or a Form ADV owner. The fund page carries the LP’s reported performance.
Timeline
4 dated events
- Sep 16, 2026Michael Liang (Managing Partner) no longer on the team page of Invivium CapitalPerson leftPeopleInferenceMichael LiangVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 21, 2023Invivium Capital first filed Form ADV (ERA, venture capital fund adviser exemption)First SEC adviser filingOrganizationFactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Sep 21, 2023Invivium Capital, LP first reported on Form ADV by Invivium Capital (Venture Capital Fund), GAV $10,025,000Fund first reported on Form ADVFundsFactInvivium Capital, LPSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Jul 1, 2023Nicole Frances Bramson joined Schedule A of Invivium Capital as Member
Classification history
- Sep 12, 2026Micro VC (confirmed, 95%, cls-1)venture manager, reported GAV $26.5M across 1 vehicles
Evidence
46 observations from 3 sources